Cellromax Science Co., Ltd.

KOSDAQ-471820
KOSDAQ
Services Non-operating Establishments
Global Rank
#31566
Country Rank
#1822
Market Cap
48.14 M
Price
3.59
Change (%)
0.38%
Volume
0

Cellromax Science Co., Ltd.'s latest marketcap:

48.14 M

As of 04/30/2026, Cellromax Science Co., Ltd.'s market capitalization has reached $48.14 M. According to our data, Cellromax Science Co., Ltd. is the 31566th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 48.14 M
Revenue (ttm) 15.01 M
Net Income (ttm) 2.01 M
Shares Out 11.2 M
EPS (ttm) 0.18
Forward PE 0.00
Ex-Dividend Date 03/30/2026
Earnings Date 05/21/2026
Market Cap Chart
Data Updated: 04/30/2026

Cellromax Science Co., Ltd.'s yearly market capitalization.

Cellromax Science Co., Ltd. has seen its market value drop from ₩57.23 B to ₩52.5 B since 2024, representing a total decrease of 8.27% and an annual compound decline rate (CAGR) of 5.89%.
Date Market Cap(₩) Market Cap(USD) Change (%) Global Rank
06/02/2026 ₩52.5 B $34.69 M -28.64% n/a
12/30/2025 ₩73.57 B $50 M 28.56% n/a
12/30/2024 ₩57.23 B $38.34 M n/a

Company Profile

Cellromax Science Co., Ltd. focuses to merge with other companies. The company was founded in 2022 and is based in Seoul, South Korea.

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.